BMS To Take Over Novartis Plant In Effort To Boost Viral Vector Production For CAR-Ts
Executive Summary
BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.
You may also be interested in...
Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves
KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.
Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.